CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
F-18 FDG +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03125629
NCT03125629Phase 2Completed

Comparison of PET/CT vs. PET/MRI

Stanford University·interventional·Posted Apr 24, 2017·Updated Apr 9, 2021

In Brief

A Phase 2 clinical trial evaluating F-18 FDG, Ga-68-DOTA-TATE, and 2 other interventions for Cancer Diagnosis and 2 related conditions. Completed, enrolled 53 participants across 1 site.

Detailed Summary

This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 24, 2017
Enrollment StartMay 27, 2014
Primary CompletionNov 30, 2016
Study CompletionFeb 5, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.2 years ago

Interventions

F-18 FDGdrug

Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging

Ga-68-DOTA-TATEdrug

Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging

Positron Emission Tomography / Computed Tomography (PET/CT) Scandevice

Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scandevice

Scan using a NOVEL GE PET/MRI scanner.